Study of Different Therapeutic Agents for the Prevention of Ischemia Reperfusion Injury in Free Skin Flap

Document Type : Original Article

Authors

1 The Departments of Plastic Surgery, Faculty of Medicine, Ain Shams University

2 The Departments of Pathology, Faculty of Medicine, Ain Shams University

3 The Departments of Plastic Surgery , Faculty of Medicine, Ain Shams University

Abstract

Background: In clinical practice a certain fraction of skin
flap transfers fail invariably because of ischemia-reperfusion
injury. This study was designed to develop experimental model
of ischemia-reperfusion injury in rat skin flap to investigate
the effect of certain pharmacological agents on prevention or
reducing ischemia-reperfusion injury.
Methods: A “4x6” cm hemi epigastric skin flap of adult
albino rat was raised and subjected to 8 hours of ischemia
then reperfusion for 48 hours. A total of 40 flaps were studied
and divided randomly into 5 groups. 15 minutes prior to
reperfusion, all flaps (except group I) were infused by saline,
Vitamin C, Heparin, and Monoclonal antibody LY-6G to
groups II, III, IV and V respectively. After 2 days, macroscopic
evaluation of flap survival, histological study of neutrophil
infiltration, and biochemical tissue enzymes assay were
performed.
Results: All flaps survived completely in sham group I
with minimal neutrophilia while the mean percentage of flap < br />necrosis in control group II was 90.5% with massive neutrophilia.
The mean percentage of flap survival were 71, 80,
and 84 percent in groups III, IV, and V respectively. Neutrophil
count of flap tissue showed significant reduction as compared
with control flaps. Tissue enzymes assay showed stable level
of superoxide dismutase activity in flaps pretreated by drugs
compared to control group. Caspase-3 enzyme activity showed
variable decrements in flaps pretreated with the different
drugs when compared with control flaps.
Conclusion: The use of certain pharmacological agents
could significantly reduce the effect of ischemia-reperfusion
injury on skin flaps.

Keywords

Main Subjects


1- Ames A. 3rd, Wright R.L., Kowada M., Thurston J.M.
and Majno G.: Cerebral ischemia. II. The no-reflow
phenomenon. Am. J. Pathol., 52 (2): 437-453, 1968.
Egypt, J. Plast. Reconstr. Surg., January 2019 99
2- May J.W. Jr., Chait L.A., O'Brien B.M. and Hurley J.V.:
The no-reflow phenomenon in experimental free flaps.
Plast. Reconstr. Surg., 61 (2): 256-67, 1978.
3- Kroll S.S., Schusterman M.A., Reece G.P., Miller M.J.,
Evans G.R., Robb G.L. and Baldwin B.J.: Choice of flap
and incidence of free flap success. Plast. Reconstr. Surg.,
98 (3): 459-63, 1996.
4- Bui D.T., Cordeiro P.G., Hu Q.-Y., Disa J.J., Pusic A. and
Mehrara B.J.: Free flap reexploration: Indications, treatment,
and outcomes in 1193 free flaps. Plast. Reconstr.
Surg., 119: 2092, 2007.
5- Davis Sears E. and Chung K.C.: Replantation of finger
avulsion injuries: A systematic review of survival and
functional outcomes. J. Hand Surg. Am., 36: 686-694,
2011.
6- Suominen S. and Asko-Seljavaara S.: Free flap failures.
Microsurgery, 16: 396, 1995.
7- Schmidt Y., Bannasch H. and Eisenhardt S.U.: Ischemiareperfusion
injury leads to significant tissue damage in
free flap surgery. Plast. Reconstr. Surg., 129 (1): 174e-
175e, 2012.
8- Kerrigan C.L. and Daniel R.K.: Pharmacologic treatment
of the failing skin flap. Plast. Reconstr. Surg. Nov., 70
(5): 541-9, 1982.
9- Wray R.C. Jr. and Young V.L.: Drug treatment and flap
survival. Plast. Reconstr. Surg.,73 (6): 939-42, 1984.
10- Pang C.Y., Forrest C.R. and Mounsey R.: Pharmacologic
intervention in ischemia-induced reperfusion injury in
the skeletal muscle. Microsurgery, 14 (3): 176-82, 1993.
11- Knight K.R.: Review of postoperative pharmacological
infusions in ischemic skin flaps. Microsurgery, 15: 675-
684, 1994.
12- Zaccaria A., Weinzweig N., Yoshitake M., et al.: Vitamin
C reduces ischemia-reperfusion injury in a rat epigastric
island skin flap model. Ann. Plast. Surg., 33: 620-623,
1994.
13- Li X., Cooley B.C., Fowler J.D. and Gould J.S.: Intravascular
heparin protects muscle flaps from ischemia / reperfusion
injury. Microsurgery, 16 (2): 90-93, 1995.
14- Tosa Y., Lee W.P., Kollias N., Randolph M.A. and May
J.W.: Monoclonal antibody to intercellular adhesion
molecule 1 protects skin flaps against ischemia-reperfusion
injury: An experimental study in rats. Plast. Reconstr.
Surg., 10: 1586-94, 1998.
15- Cahoon N.J., Naparus A., Ashrafpour H., Hofer S.O.,
Huang N., Lipa J.E., Forrest C.R. and Pang C.Y.: Pharmacologic
prophylactic treatment for perioperative protection
of skeletal muscle from ischemia-reperfusion
injury in reconstructive surgery. Plast. Reconstr. Surg.,
131 (3): 473-85, 2013.
16- Feller A.M., Roth A.C., Russell R.C., Eagleton B., Suchy
H. and Debs N.: Experimental evaluation of oxygen free
radical scavengers in the prevention of reperfusion injury
to skeletal muscle. Ann. Plast. Surg., 22: 321-331, 1989.
17- Van den Heuvel M.G., Bast A., Haenen G.R., Ambergen
A.W., Mermans J.F. and van der Hulst R.R.: The role of
antioxidants in ischemia-reperfusion in a human DIEP
flap model. J. Plast. Reconstr. Aesthet. Surg., 65 (12):
1706-11, 2012.
18- Yin Z., Ren H., Liu L., Chen W., Gan C., Jiao H. and Fan
J.: Thioredoxin Protects Skin Flaps from Ischemia-
Reperfusion Injury: A Novel Prognostic and Therapeutic
Target. Plast. Reconstr. Surg., 137 (2): 511-21, 2016.
19- Wright J.G., Kerr J.C., Valeri C.R. and Hobson R.W. 2nd:
Heparin decreases ischemia-reperfusion injury in isolated
canine gracilis model. Arch. Surg., 123 (4): 470-2, 1988.
20- Hobson R.W. 2nd, Neville R., Watanabe B., Canady J.,
Wright J.G. and Belkin M.: Role of heparin in reducing
skeletal muscle infarction in ischemia-reperfusion. Microcirc
Endothelium Lymphatics, 5 (3-5): 259-76, 1989.
21- Gedik H.S., Korkmaz K., Erdem H., Karakilic E., Lafci
G. and Ankarali H.: Protective effect of heparin in the
end organ ischemia/reperfusion injury of the lungs and
heart. J. Cardiothoracic. Surg., 15 (7): 123, 2012.
22- Yener A.Ü., Çiçek M.C., Genç S.B., Özkan T., Dog˘an E.,
Bilgin B.C., Akın T., Erdem H. and Ankarali H.: Protective
role of heparin in the injury of the liver and kidney on
the experimental model of ischemia/reperfusion. J. Cardiothorac.
Surg.,17 (9): 35, 2014.
23- Mousavi S., Moradi M., Khorshidahmad T. and Motamedi
M.: Anti-Inflammatory Effects of Heparin and Its Derivatives:
A Systematic Review. Adv. Pharmacol. Sci., 2015:
507151, 2015.
24- Lever R., Hoult J.R. and Page C.P.: The effects of heparin
and related molecules upon the adhesion of human polymorphonuclear
leucocytes to vascular endothelium in
vitro. Br. J. Pharmacol., 129: 533-40, 2000.
25- Dandona P., Qutob T., Hamouda W., Bakri F., Aljada A.
and Kumbkarni Y.: Heparin inhibits reactive oxygen
species generation by polymorphonuclear and mononuclear
leucocytes. Thromb. Res., 15; 96 (6): 437-43, 1999.
26- Thourani V.H., Brar S.S., Kennedy T.P., Thornton L.R.,
Watts J.A., Ronson R.S., Zhao Z.Q., Sturrock A.L., Hoidal
J.R. and Vinten-Johansen J.: Nonanticoagulant heparin
inhibits NF-kappaB activation and attenuates myocardial
reperfusion injury. Am. J. Physiol. Heart Circ. Physiol.,
278 (6): H2084-93, 2000.
27- Cotran R.S. and Pober J.S.: Cytokine-endothelial interactions
in inflammation, immunity, and vascular injury. J.
Am. Soc. Nephrol., 1 (3): 225-35, 1990.
28- Zamboni W.A., Stephenson L.L., Roth A.C., Suchy H.
and Russell R.C.: Ischemia-reperfusion injury in skeletal
muscle: CD 18-dependent neutrophil-endothelial adhesion
and arteriolar vasoconstriction. Plast. Reconstr. Surg., 99
(7): 2002-7, 1997.
29- Petrasek P.F., Liauw S., Romaschin A.D. and Walker P.M.:
Salvage of postischemic skeletal muscle by monoclonal
antibody blockade of neutrophil adhesion molecule CD18.
J. Surg. Res., 56 (1): 5-12, 1994.
30- Sasaki G.H. and Pang C.Y.: Hemodynamics and viability
of acute neurovascular island skin flaps in rats. Plast.
Reconsfr. Surg., 65: 152-158, 1980.
31- Georgopoulos S., Mastorakos D., Kondi-Pafiti A., Katsenis
K., Arkadopoulos N., Kannas D., Archontaki M., Vestarchis
N. and Kokkalis G.: Hydroxyzine, cimetidine and
vitamin C in reducing skin flap necrosis in ischemiareperfusion
injury in rats. A comparative study. J. BUON,
17 (2): 377-82, 2012.
32- Faham S., Hileman R.E., Fromm J.R., Linhardt R.J. and
Rees D.C.: Heparin structure and interactions with basic
fibroblast growth factor. Science, 271: 1116-1120, 1996.
33- Jones H., Paul W. and Page C.P.: The effects of heparin
and related molecules on vascular permeability and neutrophil
accumulation in rabbit skin. Br. J. Pharmacol.,
135 (2): 469-79, 2002.
34- Hiebert L.M., Ping T. and Wice S.M.: Enhanced antithrombotic
effects of unfractionated heparin in rats after repeated
oral doses and its relationship to endothelial heparin
concentration. Br. J. Pharmacol., 153 (6): 1177-1184,
2008.
35- Hirigoyen M.B., Zhang W., Gordon R.E., Prabhat A.,
Urken M.L. and Weinberg H.: Additional benefit of heparin
in the thrombolytic salvage of ischemic skin flaps. Ann.
Plast. Surg., 35 (6): 612-9, 1995.
36- Springer T.A.: Adhesion receptors of the immune system.
Nature, 2; 346 (6283): 425-34, 1990.
37- Patarroyo M.: Leukocyte adhesion in host defense and
tissue injury. Clin. Immunol. Immunopathol., 60 (3): 333-
48, 1991.
38- Hubbard A.K. and Rothlein R.: Intercellular adhesion
molecule-1 (ICAM-1) expression and cell signaling cascades.
Free Radic. Biol. Med., 1; 28 (9): 1379-86, 2000.
39- Winn R.K., Ramamoorthy C., Vedder N.B., Sharar S.R.
and Harlan J.M.: Leukocyte-endothelial cell interactions
in ischemia-reperfusion injury. Ann. N. Y. Acad. Sci.,
832: 311-321, 1997.
100 Vol. 43, No. 1 / Study of Different Therapeutic Agents for the Prevention
40- Petrasek P.F., Liauw S., Romaschin A.D. and Walker P.M.:
Salvage of postischemic skeletal muscle by monoclonal
antibody blockade of neutrophil adhesion molecule CD18.
J. Surg. Res., 56 (1): 5-12, 1994.
41- Rabb H., O'Meara Y.M., Maderna P., Coleman P. and
Brady H.R.: Leukocytes, cell adhesion molecules and
ischemic acute renal failure. Kidney Int., 51 (5): 1463-
8, 1997.
42- DEMIRSEREN M.E., SARICI M., GOKREM S. and
YENIDUNYA S.: Protective effects of monoclonal antibody
to intercellular adhesion molecule-1 in venous
ischemia-reperfusion injury: Experimental study in rats.
J. Reconstr. Microsurg., 23 (1): 41-4, 2007.
43- Pan B.H., Tosa Y., Hosaka Y., Satoh K., Yokoyama T.,
SAIGA A. and Yenidunya M.O.: Effect of Monoclonal
Antibody to P-Selectin on Ischemia-Reperfusion Injury
in Skin Flap. Showa Univ. J. Med. Sci., 20 (1): 1-10,
2008.
44- Fukai T. and Ushio-Fukai M.: Superoxide dismutases:
Role in redox signaling, vascular function, and diseases.
Antioxid Redox Signal, 15; 15 (6): 1583-606, 2011.
45- Perry J.J., Shin D.S., Getzoff E.D. and Tainer J.A.: The
structural biochemistry of the superoxide dismutases.
Biochim. Biophys. Acta., 1804 (2): 245-62, 2010.
46- Klein M.B., Chan P.H. and Chang J.: Protective effects
of superoxide dismutase against ischemia-reperfusion
injury: development and application of a transgenic animal
model. Plast. Reconstr. Surg., 111 (1): 251-5, 2003